• Earlier this week, RBC Capital resumed coverage of Bio-Rad Laboratories, assigning an Outperform rating and emphasizing expectations for improved margins under new leadership and a recovery from product-specific challenges anticipated in 2026.
• RBC’s focus on a 2027 sales rebound and structurally stronger profitability highlights how management execution and product mix could reshape Bio-Rad’s longer-term outlook.
• Now, we’ll examine how RBC’s renewed confidence in Bio-Rad’s margin improvement potential may influence the company’s existing investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Bio-Rad Laboratories Investment Narrative Recap

To own Bio Rad today, you need to believe its life science and diagnostics portfolio can weather weak instrument demand and reimbursement pressure while management works to stabilize margins. RBC’s renewed Outperform rating, with an emphasis on margin improvement under new leadership and a 2027 sales recovery, reinforces margin repair as the key near term catalyst. It does not materially change the core risk that prolonged softness in research and clinical demand could keep gross margins under pressure.

Among recent developments, the completion of roughly US$762.9 million in share repurchases since 2023 is particularly relevant. With RBC now highlighting structurally stronger profitability, that sizeable buyback program matters more, because it has already reduced the share count into any future margin improvement. For investors focused on catalysts, the combination of ongoing ddPCR platform rollouts, the Stilla acquisition, and a tighter capital base all tie directly into the margin story RBC is underscoring.

Yet beneath the margin optimism, investors should be aware of the risk that persistent weakness in core life science products and academic funding could...

Bio-Rad Laboratories' narrative projects $2.7 billion revenue and $226.1 million earnings by 2029. This requires 1.2% yearly revenue growth and a $57.3 million earnings increase from $168.8 million today.

Uncover how Bio-Rad Laboratories' forecasts yield a $293.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

RBC’s upbeat view sits closer to the most optimistic analysts, who were assuming roughly US$2.8 billion of revenue and US$264.5 million of earnings by 2029, even while warning that rising SG&A and Stilla integration costs could keep margins under strain. That is a much more optimistic stance than consensus, and with this new coverage in play, it is worth recognizing how far expectations can stretch and how they might shift as fresh information arrives.

Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth just $286.20!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

No Opportunity In Bio-Rad Laboratories?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.